Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. A prospective double-blind arteriographically controlled trial

Lancet. 1985 Feb 23;1(8426):415-9. doi: 10.1016/s0140-6736(85)91144-4.


240 patients were admitted to a double-blind study to determine the effect of long-term treatment with platelet-function inhibiting agents on occlusive arterial disease in the lower extremities. Patients were randomised into 1 of 3 treatment groups: aspirin 330 mg; dipyridamole 75 mg and aspirin 330 mg; or matching placebo 3 times daily. The duration of treatment was 2 years. Arteriography was carried out at the beginning of the study and 2 years later or before if deterioration was observed. 199 patients completed the study according to the trial protocol. The serial arteriograms were assessed in pairs qualitatively, by means of simple comparative viewing, and semiquantitatively with Bollinger's score system. Progression of the disease was most pronounced in the placebo-treated group, less so in the aspirin-treated group, and least of all in the dipyridamole-and-aspirin group. Patients who smoke and those with hypertension may benefit most from treatment with the 2 preparations under investigation.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Arterial Occlusive Diseases / diagnostic imaging
  • Arterial Occlusive Diseases / drug therapy*
  • Aspirin / therapeutic use*
  • Blood Platelets / drug effects
  • Clinical Trials as Topic
  • Dipyridamole / therapeutic use*
  • Double-Blind Method
  • Drug Therapy, Combination
  • Extremities / blood supply
  • Female
  • Femoral Artery* / diagnostic imaging
  • Humans
  • Male
  • Middle Aged
  • Placebos
  • Popliteal Artery* / diagnostic imaging
  • Prospective Studies
  • Radiography
  • Random Allocation


  • Placebos
  • Dipyridamole
  • Aspirin